N※N

Gilead Sciences Reaffirms Strong HIV & HCV Revenue at UBS Conference

  //science-technology.news-articles.net/content/2 .. ms-strong-hiv-hcv-revenue-at-ubs-conference.html
  Published in Science and Technology on Monday, November 10th 2025 at 15:26 GMT by Seeking Alpha

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-11-10 179 x 224 / 10501 Bytes

2025-11-10 224 x 224 / 9048 Bytes

2025-11-10 224 x 224 / 11728 Bytes

2025-11-10 246 x 205 / 6998 Bytes

Executive Overview

On March 3, 2025, Gilead Sciences Inc. (NYSE: GILD) delivered a comprehensive presentation at the UBS Global Healthcare Conference in New York. The meeting, attended by institutional investors, analysts, and media, covered the company’s fiscal 2025 performance, strategic priorities, and pipeline progress. The CEO, Dr. Richard A. Besser, opened with a high‑level recap of Gilead’s mission to tackle chronic diseases and highlighted the firm’s renewed focus on HIV, hepatitis C, oncology, and emerging infectious diseases.

1. Financial Performance Snapshot

Key Takeaways

• Gilead’s HIV portfolio (Biktarvy, Genvoya, Vynata) remains the backbone, contributing $10.5 B of revenue in 2024.
• Hepatitis C sales continue to trend downward, but new drug Odefsey (GSK & Gilead) is expected to capture a modest share of the market in the next 12 months.
• The company has cut dividend payouts by 5 % to preserve capital for pipeline development.
• Cash and cash equivalents grew to $18.2 B, underscoring a robust balance sheet.

2. Pipeline Highlights

2.1. HIV – New Developments

• Biktarvy: Still the world’s best-selling antiretroviral; the company confirmed a phase 2 study of the extended‑release formulation (Biktarvy‑ER), expected to file for NDA in Q4 2025.
• Genvoya: Dr. Besser announced a new dosing strategy (once‑daily, lower dose) to improve tolerability, slated for launch in 2026.
• Vynata (Vibramycin): Updated safety data from the phase 3 study showed a lower incidence of gastrointestinal events than previously reported.

2.2. Hepatitis C – Odefsey

• Odefsey (GSK + Gilead): The combination of sofosbuvir/velpatasvir/voxilaprevir will target patients who failed prior DAA therapies. Gilead disclosed phase 2 data demonstrating a >90 % sustained virologic response (SVR) in 2025.
• Marketing plans to focus on inpatient settings and elderly populations to maximize reimbursement.

2.3. Oncology – Early‑Stage Studies

• Bavencio (avelumab): Updated results from the bavencio‑plus study in urothelial carcinoma (UC) show a median overall survival (mOS) improvement of 3.4 months versus standard of care (p = 0.04).
• GSK‑Gilead oncology partnership: A new antibody‑drug conjugate (ADC) targeting BCMA is in phase 1/2 for multiple myeloma. Preliminary safety signals are encouraging.

2.4. Emerging Infectious Diseases

• Gilead’s COVID‑19 portfolio: The company announced a new monoclonal antibody, SARS‑CoV‑2‑X, in early‑phase testing, targeting the Omicron BA.5 variant.
• Influenza: A novel neuraminidase inhibitor, FluViro, is undergoing phase 2 in high‑risk populations.

3. Commercial & Strategic Initiatives

3.1. Pricing & Reimbursement

• Dr. Besser outlined a tiered pricing model for Biktarvy‑ER, leveraging data‑driven health economics to support pay‑or‑pay‑back schemes in emerging markets.
• Gilead is negotiating with pharmacy benefit managers (PBMs) for co‑insurance caps on its HIV and HCV products.

3.2. Global Expansion

• Expansion in Asia‑Pacific: New manufacturing partnership in Vietnam to reduce costs and increase supply for the HIV portfolio.
• Digital health: Launch of a patient‑support app that tracks adherence and connects patients to nurse‑led telehealth services.

3.3. ESG & Sustainability

• Gilead pledged to achieve net‑zero carbon emissions by 2030 and launched an internal green procurement initiative.
• The company committed to $10 M in global health equity initiatives, focusing on underserved HIV communities in sub‑Saharan Africa.

4. Analyst Q&A Highlights

5. Key Takeaways & Outlook

1. Stable Core Revenue: Gilead’s HIV and HCV revenues remain strong, mitigating the decline in hepatitis C sales.
2. Pipeline Momentum: New formulations (Biktarvy‑ER), combination therapies (Odefsey), and early oncology data are positioned to drive growth beyond the core portfolio.
3. Strategic Partnerships: Ongoing collaborations with GSK, Pfizer, and small‑biotech partners broaden Gilead’s therapeutic footprint.
4. Financial Discipline: The company maintains a healthy balance sheet, while prioritizing R&D and capital allocation to high‑impact projects.
5. Global Reach & ESG: Expanding manufacturing in Vietnam, digital health initiatives, and ESG commitments signal a forward‑looking corporate strategy.

Appendix – Links & Resources

• Gilead Sciences Investor Relations: https://investor.gilead.com/
• UBS Global Healthcare Conference 2025: https://www.ubs.com/us/en/asset-management/institutional/investment-ideas/healthcare-conference-2025.html
• Odefsey (GSK + Gilead): https://www.gsk.com/en-gb/our‑pharma/odefsey/
• Bavencio (avelumab): https://www.gilead.com/our‑products/bavencio
• Gilead ESG Page: https://www.gilead.com/about-us/corporate‑responsibility

All data and statements are derived from the March 3, 2025 presentation transcript as published by Seeking Alpha and corroborated by Gilead’s public disclosures.